Overview

A Trial of TTI-621 for Patients With Hematologic Malignancies and Selected Solid Tumors

Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Multicenter, open-label, phase 1a/1b trial of TTI-621 in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Trillium Therapeutics Inc.
Treatments:
Immunoglobulin G
Nivolumab
Rituximab